Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock

Zevra Therapeutics Director Corey Michael Watton sold 12,300 shares of the company's stock for $138,375.00, reducing his holdings by 87.23% to 1,800 shares. This transaction follows a strong quarterly earnings report where ZVRA exceeded both EPS and revenue estimates. Analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target of $27.14 despite one recent price target cut.